1
|
Sereff SB, Daniels MW, Wittliff JL. Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas. J Clin Lab Anal 2019; 33:e22982. [PMID: 31359505 PMCID: PMC6868412 DOI: 10.1002/jcla.22982] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2019] [Revised: 06/30/2019] [Accepted: 07/01/2019] [Indexed: 01/20/2023] Open
Abstract
Background uPA, its receptor uPAR, and inhibitors PAI‐1 and PAI‐2 play key roles in membrane remodeling/invasion and in predicting response to chemotherapy. We identified novel relationships of these biomarkers with ER/PR that indicate clinical utility for assessing breast carcinoma outcomes. Methods Retrospective studies were performed with de‐identified results of (a) uPA, uPAR, and PAI‐1; (b) estrogen (ER) and progestin receptor (PR); and (c) clinical outcomes. Relative expression of 22 000 genes from microarray of RNA from LCM‐procured breast cancer cells was used with R Studio version 3.4.1. Results Primary ER/PR status was related to uPA, uPAR, or PAI‐1 levels. ER− or PR− cancers expressed elevated uPA, uPAR, and PAI2 mRNA compared to ER+ or PR+ cells. Inverse relationships between ER/PR protein and expression of uPA, uPAR, and PAI‐2 were observed, whereas HER2 status was unrelated. qPCR analyses showed RERG and NQO‐1 expressions were elevated in uPA− lesions, while CD34 and EDG‐1 were elevated in uPAR− cancers. ERBB4 was overexpressed in PAI‐1+ carcinomas. Cox regression analyses revealed relationships of ER/PR status and uPA system members with regard to clinical outcomes of breast cancer. Conclusions uPA, uPAR, PAI1, or PAI2 expression was increased in either ER− or PR− cancers similar to that of protein content in ER−/PR− carcinomas, suggesting sex hormones regulate the uPA system in breast cancer. Results revealed protein content of uPA system members was related to ER/PR status of primary lesions. Use of LCM‐procured carcinoma cells uncovered relationships between expression of known cancer−associated genes and protein content of uPA system members. Collectively, results indicate evaluation of ER and PR protein of primary breast cancers combined with analyses of uPA, uPAR, and PAI‐1 protein content improves assessment of clinical outcomes.
Collapse
Affiliation(s)
- Seth B Sereff
- Department of Biochemistry & Molecular Genetics, University of Louisville, Louisville, Kentucky.,Institute for Molecular Diversity & Drug Design, University of Louisville, Louisville, Kentucky
| | - Michael W Daniels
- Department of Biochemistry & Molecular Genetics, University of Louisville, Louisville, Kentucky.,Department of Biostatistics, University of Colorado at Aurora, Aurora, Colorado
| | - James L Wittliff
- Department of Biochemistry & Molecular Genetics, University of Louisville, Louisville, Kentucky.,Institute for Molecular Diversity & Drug Design, University of Louisville, Louisville, Kentucky
| |
Collapse
|
2
|
Clemons TD, Singh R, Sorolla A, Chaudhari N, Hubbard A, Iyer KS. Distinction Between Active and Passive Targeting of Nanoparticles Dictate Their Overall Therapeutic Efficacy. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2018; 34:15343-15349. [PMID: 30441895 DOI: 10.1021/acs.langmuir.8b02946] [Citation(s) in RCA: 89] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
The role of nanoparticles in cancer medicine is vast with debate still surrounding the distinction between therapeutic efficacy of actively targeted nanoparticles versus passively targeted systems for drug delivery. While it is commonly accepted that methodologies that result in homing a high concentration of drug loaded nanoparticles to the tumor is beneficial, the role of intracellular trafficking of these nanoparticles in dictating the overall therapeutic outcome remains unresolved. Herein we demonstrate that the therapeutic outcome of drug loaded nanoparticles is governed beyond simply enabling nanoparticle internalization in cells. Using two model polymeric nanoparticles, one decorated with the GE11 peptide for active targeting of the epidermal growth factor receptor (EGFR) and the other without, we demonstrate that EGFR mediated intracellular internalization results in an enhanced therapeutic effect compared to the nontargeted formulation. Our findings demonstrate that the intracellular destination of nanoparticles beyond its ability to internalize is an important parameter that has to be accounted for in the design of targeted drug delivery systems.
Collapse
Affiliation(s)
- Tristan D Clemons
- School of Molecular Sciences , University of Western Australia , 35 Stirling Highway , Crawley , Western Australia Australia , 6009
| | - Ruhani Singh
- School of Molecular Sciences , University of Western Australia , 35 Stirling Highway , Crawley , Western Australia Australia , 6009
- CSIRO Manufacturing , New Horizons Centre , 20 Research Way , Clayton , Victoria Australia 3168
| | - Anabel Sorolla
- Harry Perkins Institute of Medical Research , 6 Verdun Street , Nedlands , Western Australia Australia 6009
| | - Nutan Chaudhari
- School of Molecular Sciences , University of Western Australia , 35 Stirling Highway , Crawley , Western Australia Australia , 6009
| | - Alysia Hubbard
- Centre for Microscopy, Characterisation and Analysis , University of Western Australia , 35 Stirling Highway , Crawley , Western Australia Australia , 6009
| | - K Swaminatha Iyer
- School of Molecular Sciences , University of Western Australia , 35 Stirling Highway , Crawley , Western Australia Australia , 6009
| |
Collapse
|
3
|
Arifler D. Nanoplatform-based optical contrast enhancement in epithelial tissues: quantitative analysis via Monte Carlo simulations and implications on precancer diagnostics. OPTICS EXPRESS 2013; 21:3693-3707. [PMID: 23481825 DOI: 10.1364/oe.21.003693] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
This paper presents a comprehensive computational analysis of the spectral optical response of epithelial tissues labeled with gold nanoparticles. Monte Carlo modeling is employed to simulate nanoparticle-induced changes in reflectance signals and to assess whether labeling can generate sufficient exogenous contrast that can better pinpoint precancer progression. Simulation results suggest that the observed contrast profile is highly dependent on a series of factors including the labeling scheme, optical sensor geometry, and wavelength. It is evident, however, that selection of an optimal labeling and sensing strategy can lead to a significant enhancement of the inherent positive or negative contrast and can improve the diagnostic potential of optical measurements.
Collapse
Affiliation(s)
- Dizem Arifler
- Division of Cancer Research, Kemal Saracoglu Foundation for Children with Leukemia and Fight Against Cancer, Nicosia, Cyprus.
| |
Collapse
|
4
|
Andres SA, Edwards AB, Wittliff JL. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance. J Clin Lab Anal 2012; 26:93-103. [PMID: 22467324 DOI: 10.1002/jcla.21488] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Serine proteases convert plasminogen to plasmin which is involved in tissue remodeling under physiologic and pathophysiologic conditions, including breast carcinoma invasion and progression. Both urokinase-type plasminogen activator (uPA) and pro-uPA associate with uPA receptor (uPAR) on target cells, where plasminogen activator inhibitors (e.g., PAI-1) may modulate their activities. Expression levels of these factors were compared in breast carcinomas relative to patient characteristics, carcinoma features, and clinical outcome. uPA, uPAR, and PAI-1 were quantified by enzyme-linked immunosorbent assay (ELISA) in extracts of 226 biopsies while estrogen receptor (ER) and progestin receptor (PR) were determined by enzyme immunoassay (EIA) or radio-ligand binding. Each set of assays contained a novel reference specimen with known quantities of each of these five analytes. Levels in ng/mg protein of these biomarkers exhibited ranges: uPA (0-12.3); uPAR (0-19.5); PAI-1 (0-91.2). When considered independently, expression of uPA, uPAR, or PAI-1 was unrelated to patient age or menopausal status. Although no correlation was observed between each analyte with stage, grade, or ER/PR status, levels appeared to differ with pathology and nodal status. A dendrogram from hierarchical clustering of uPA, uPAR, and PAI-1 levels in 106 specimens revealed three clusters of breast cancer patients. Kaplan-Meier analyses of uPA, uPAR, and PAI-1 indicated a correlation with overall survival (OS), suggesting collective examination of these biomarkers is useful in predicting clinical outcome of breast cancer.
Collapse
Affiliation(s)
- Sarah A Andres
- Department of Biochemistry & Molecular Biology, Institute for Molecular Diversity & Drug Design, University of Louisville, Louisville, Kentucky 40292, USA
| | | | | |
Collapse
|
5
|
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. NATURE NANOTECHNOLOGY 2007; 2:751-60. [PMID: 18654426 DOI: 10.1038/nnano.2007.387] [Citation(s) in RCA: 5837] [Impact Index Per Article: 343.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/14/2023]
Abstract
Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. Several therapeutic nanocarriers have been approved for clinical use. However, to date, there are only a few clinically approved nanocarriers that incorporate molecules to selectively bind and target cancer cells. This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic. We detail the arsenal of nanocarriers and molecules available for selective tumour targeting, and emphasize the challenges in cancer treatment.
Collapse
Affiliation(s)
- Dan Peer
- Department of Anesthesia, Immune Disease Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
| | | | | | | | | | | |
Collapse
|
6
|
Bhattacherjee V, Greene R, Pisano MM. Cambridge Healthtech Institute's 3rd Annual Laser Capture Microscopy: cutting edge applications. May 2-3 2005, World Trade Center, Boston, MA, USA. Expert Rev Mol Diagn 2005; 5:487-91. [PMID: 16013966 DOI: 10.1586/14737159.5.4.487] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Vasker Bhattacherjee
- The Laboratory of Craniofacial Development, University of Louisville Birth Defects Center, 501 S. Preston Street, Suite 301, Louisville, KY 40202, USA.
| | | | | |
Collapse
|
7
|
Abstract
Evaluation of the genome has provided information concerning the origins of many human diseases, including cancer. Identification of the genes and their protein products has greatly increased our understanding of this complex disease. A variety of cellular processes and pathways stimulate cellular proliferation or inhibit cell death. Many of these pathways are targets for novel therapeutic agents. These agents will usher in a new era of biologically targeted therapeutics. In gynecologic oncology, we are just beginning to investigate these new biologic agents. An appreciation and understanding of these pathways of growth deregulation in gynecologic cancers provide an opportunity for many clinically relevant therapies. This review summarizes the emerging biologic therapies with an emphasis on their relevance to gynecologic malignancies.
Collapse
Affiliation(s)
- John H Farley
- Tripler Army Medical Center, Division of Gyencologic Oncology, USA
| | | |
Collapse
|
8
|
Saygili U, Koyuncuoglu M, Altunyurt S, Guclu S, Uslu T, Erten O. May cathepsin D immunoreactivity be used as a prognostic factor in endometrial carcinomas? A comparative immunohistochemical study. Gynecol Oncol 2001; 83:20-4. [PMID: 11585409 DOI: 10.1006/gyno.2001.6348] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE To investigate the prognostic value of immunohistochemical detection of cathepsin D and the association between cathepsin D and established prognostic factors in endometrial carcinoma. METHODS Cathepsin D immunoreactivity was determined by an immunohistochemical technique in a series of 79 patients with surgical stage I-III primary endometrial carcinoma. RESULTS Of 79 tissue specimens, 48 (61%) showed a positive reaction for cathepsin D. A significant correlation between cathepsin D and histological grade was found (P < 0.05). The other established clinicopathological prognostic factors were not associated with cathepsin D. There was not any significant difference in prognosis between the positive cases and negative cases for cathepsin D (P > 0.05). In the univariate analysis cathepsin D immunoreactivity did not show significant prognostic value for overall survival (P > 0.05). The multivariate analysis also showed that cathepsin D was not related to patient outcome (P = 0.24, relative risk = 0.34, 95% confidence interval = 0.05-2.09). CONCLUSIONS Our results suggest that cathepsin D immunoreactivity may not be of prognostic value but more studies are needed to evaluate the relationship between its immunoreactivity in tumor cells and in other cells.
Collapse
Affiliation(s)
- U Saygili
- Department of Obstetrics and Gynecology, Dokuz Eylül University School of Medicine, Izmir, Turkey.
| | | | | | | | | | | |
Collapse
|
9
|
Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. Gynecol Oncol 2001; 80:48-55. [PMID: 11136569 DOI: 10.1006/gyno.2000.6015] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE Tumor invasion involves degradation of extracellular matrix. The urokinase plasminogen activation system participates in this process. Urokinase-type plasminogen activator (uPA), its receptor (uPAR), and its inhibitor, plasminogen activator inhibitor type 1 (PAI-1), are proposed to be prognostic factors in some cancers. There are conflicting data regarding the prognostic role of this system in endometrial cancer. METHODS To determine the prognostic value of the urokinase plasminogen activation system, contents of uPA, uPAR, and PAI-1 were measured in extracts of endometrial cancer tissue using ELISAs. uPA, uPAR, and PAI-1 levels were determined in 91, 54, and 92 extracts, respectively, and correlated with tumor histology, stage, grade, lymph node involvement, prevalence of metastasis, and recurrence as well as with estrogen (ER), progesterone (PR), epidermal growth factor (EGFR) receptor and HER-2/neu contents. RESULTS Patients with cancers exhibiting advanced stage, high grade, unfavorable tumor histology, nodal involvement, recurrence, and lower PR levels determined by ligand binding had significantly higher uPA content than others. PAI-1 was significantly elevated in patients with advanced stage, high-grade tumor, recurrence, decreased ER content, and lower PR levels determined by ligand binding. uPAR did not show any relation to any of clinical and laboratory parameters. Elevated expression of PAI-1 was associated with significantly shorter disease-free (P = 0.005) and overall (P = 0.0003) survival. Multivariate analysis revealed that PAI-1 was a predictor of survival although stage was the strongest independent factor. CONCLUSION Elevated uPA and PAI-1 levels appear to correlate with unfavorable prognosis in endometrial cancer.
Collapse
Affiliation(s)
- C Tecimer
- Hormone Receptor Laboratory, University of Louisville, Louisville, Kentucky 40202, USA.
| | | | | | | | | | | |
Collapse
|
10
|
Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. Int J Gynecol Cancer 2000; 10:372-381. [PMID: 11240701 DOI: 10.1046/j.1525-1438.2000.010005372.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Urokinase-type plasminogen activator (uPA), its receptor (uPAR) and inhibitor, plasminogen activator-type 1 (PAI-1) are proposed to be of prognostic significance in some cancers. To determine the prognostic value of the urokinase plasminogen activation system in ovarian cancer, levels of uPA, uPAR, and PAI-1 were measured in extracts of ovarian cancer tissue using ELISA tests. uPA and PAI-1 were determined in 70 tumor extracts and uPAR in 43 extracts. Levels were correlated with age, tumor histology, stage, grade, lymph node and metastatic status, residual disease, risk of recurrence, epidermal growth factor receptor (EGFR) expression, cathepsin D (Cath-D), and c-erbB-2 levels. uPA and uPAR did not exhibit correlation with any of these parameters. However, patients with high grade tumor, recurrence, and lower EGFR and Cath-D had significantly higher PAI-1 levels compared to those of others (P < 0.05). Kaplan-Meier plots of survival were compared. uPA and uPAR were not related to disease-free or overall survival. Although low PAI-1 appeared to predict a longer overall survival, the difference was not statistically significant. Multivariate analysis revealed that PAI-1 was a predictor for overall survival although it was not as strong as stage. These results suggest that elevated PAI-1 seems to be correlated with an unfavorable prognosis in ovarian cancer.
Collapse
Affiliation(s)
- C. Tecimer
- Hormone Receptor Laboratory, Division of Medical Oncology, Division of Gyn Oncology, and Health Sciences Biostatistics Center, University of Louisville, Louisville, Kentucky;St. Luke's Hospital, Chesterfield, Missouri, and Lehigh Valley Hospital, Allentown, Pennsylvania
| | | | | | | | | | | |
Collapse
|
11
|
Salazar EL, Torres JA, Avila A, Andrade A. Hyperplastic changes and receptor status in the breast tissue of bodybuilders under anabolic-androgenic steroid stimulation. ARCHIVES OF ANDROLOGY 2000; 45:1-7. [PMID: 10959495 DOI: 10.1080/014850100409945] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
Anabolic androgenic steroids (AAS) are misused by athletes to improve their physical performance. AAS with similar groups and configuration indicate that testosterone is the base of this ability to stimulate anabolic activity. The effect of these compounds on the breast tissue of males that consume them is a confirmation of its metabolic pathway. To confirm its hormonal effects, the status of estradiol and progesterone receptors (ER, PgR) status was determined in cytoplasmic and nuclear fractions (HRc, HRn) of 8 premalignant breast tissues from 8 bodybuilders (aged 21 to 45 years) under AAS stimulation. The control group included 5 males with benign disorders of the breast, but not due to AAS administration. The concentrations of ERc and ERn were significantly higher (p < .05) in males under AAS stimulation than in males without these. The concentrations of PgRc and PgRn do not differ between these two groups (p > .05) The benign breast disease is remarkably similar in female and male patients, suggesting a common origin. In the same way, the measurement of both HRc and HRn is necessary to accurately report receptor concentration.
Collapse
Affiliation(s)
- E L Salazar
- Medical Research Reproductive Biology Unit, Obstetrics and Gynecology Hospital, IMSS, Mexico City, Mexico.
| | | | | | | |
Collapse
|
12
|
Falcón O, Chirino R, León L, López-Bonilla A, Torres S, Fernández L, García-Hernández JA, Valerón PF, Díaz-Chico JC. Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer. Br J Cancer 1999; 79:570-6. [PMID: 10027332 PMCID: PMC2362431 DOI: 10.1038/sj.bjc.6690090] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Total cytosolic cathepsin D (Cat D) levels were estimated by an immunoradiometric assay in a series of 156 consecutive patients with surgical stages I-III primary endometrial adenocarcinoma. Simultaneously, the tissue content of both oestrogen (ER) and progesterone (PR) receptors, and p185HER-2/neu, DNA content (ploidy), and the fraction of S-phase cells (S-phase) were also estimated. Tumoral Cat D content ranged from 0 to 243 pmol mg(-1) protein (median 44 pmol mg(-1) protein) and was not associated with any of the established clinicopathological and biological prognostic variables, with the exception of a weak positive correlation with the tumoral p185HER-2/neu levels. Univariable analysis performed on a subset of 97 patients, followed for a minimum of 2 years or until death, showed that patient age at diagnosis, high histological grade, advanced surgical stage, vascular invasion, positive peritoneal cytology, low levels of Cat D, negative ER and PR status, aneuploidy, and high S-phase were predictive of the presence of persistent or recurrent disease. However, multivariable analysis revealed that only histological grade, surgical stage, Cat D and PR were significantly associated with the patient's outcome. From these findings, we conclude that Cat D is an independent prognostic factor in endometrial adenocarcinoma, its low levels being associated with a worse clinical outcome.
Collapse
Affiliation(s)
- O Falcón
- Department of Obstetrics and Gynaecology, Hospital Materno Infantil de Las Palmas de GC, Canary Islands, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Simaga S, Babić D, Osmak M, Ilić-Forko J, Vitale L, Milicić D, Abramić M. Dipeptidyl peptidase III in malignant and non-malignant gynaecological tissue. Eur J Cancer 1998; 34:399-405. [PMID: 9640230 DOI: 10.1016/s0959-8049(97)00401-2] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Exopeptidases, in contrast to endopeptidases (proteinases) have been much less studied in relation to cancer. The aim of this study was to investigate one such enzyme, dipeptidyl peptidase III (DPP III), in gynaecological tissues, by measuring both the enzyme activity and enzyme content. DPP III activity was assessed in normal (n = 65), benign (n = 9) and malignant (n = 51) gynaecological tissues. A statistically significant higher DPP III activity was observed in endometrial (n = 40, P = 4.6 x 10(-7)) and ovarian (n = 11, P = 8.1 x 10(-4)) malignant tumours, whereas no significant difference was detected for leiomyomas (n = 8), if compared to the activity in normal tissue. A matched pair analysis of normal and cancerous endometrial tissue confirmed the significance of the DPP III activity increase in the transformed tissue (n = 7, P = 0.022). Western blot analysis revealed a significantly (P = 0.014) increased level of DPP III in endometrial cancer. Further, regression analysis showed a positive correlation between the activity and the content of DPP III in normal tissue (r = 0.637, P = 0.047) and in endometrial cancer (r = 0.574, P < 0.007). The increase of the DPP III activity was observed in the endometrial carcinomas of various histological types, grade or the depth of myometrial invasion. The easy-to-perform determination of this exopeptidase activity may serve as a potential indicator of endometrial and ovarian malignancies.
Collapse
Affiliation(s)
- S Simaga
- Rudjer Bosković Institute, Department of Organic Chemistry and Biochemistry, Zagreb, Croatia
| | | | | | | | | | | | | |
Collapse
|
14
|
Osmak M, Babić D, Abramić M, Vrhovec I, Milicić D, Skrk J. Cathepsin D content in malignant tumours of corpus uteri. Eur J Cancer 1997; 33:699-700. [PMID: 9274460 DOI: 10.1016/s0959-8049(96)00490-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|